Superseded public profile

Not FDA-approved↗Unapproved and safety records↗↗

Superseded · version 2: Ipamorelin↗

Related names recorded in this version: Ipamorelin acetate↗

FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

We added FDA's dated assessment to distinguish substance forms, evaluated uses and the advisory stage of review. Earlier profile versions remain available. 3

What this version reported

At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗

Sources for this version

  1. 1
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  3. 3
    FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026